Publications

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Prognostic and predictive role of the tumor immune landscape.

01-06-2020

Science (New York, N.Y.)

The human tumor microbiome is composed of tumor type-specific intracellular bacteria.

29-05-2020

Journal of cancer research and therapeutics

Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma.

05-05-2020

Clinical cancer research : an official journal of the American Association for Cancer Research

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.

01-05-2020

Pigment cell & melanoma research

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.

01-05-2020

Clinical and experimental rheumatology

Acrocyanosis after neoadjuvant ipilimumab plus nivolumab: a case report.

18-04-2020

JAMA oncology

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.

01-04-2020

European urology oncology

Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.

01-04-2020

Nature medicine

Learning from clinical trials of neoadjuvant checkpoint blockade.

01-04-2020

Oncoimmunology

Lactate dehydrogenase: a marker of diminished antitumor immunity.

12-03-2020

Annals of oncology : official journal of the European Society for Medical Oncology

Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.

01-01-2020

Nature

B cells and tertiary lymphoid structures promote immunotherapy response.

01-01-2020

European journal of cancer (Oxford, England : 1990)

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

01-01-2020

Nature medicine

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

01-12-2019

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.

20-11-2019

Nature reviews. Immunology

Defining 'T cell exhaustion'.

01-11-2019

Cell reports

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy.

01-10-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.

01-10-2019

European urology

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

01-10-2019

The Lancet. Oncology

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

01-09-2019

ESMO open

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

20-08-2019

Cell

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.

25-07-2019

Cancers

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

18-07-2019

The Lancet. Oncology

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

01-07-2019

The Lancet. Oncology

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

01-07-2019

Future oncology (London, England)

A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).

01-07-2019

Nature medicine

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-07-2019

European journal of cancer (Oxford, England : 1990)

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

01-07-2019

Immuno-oncology technology

A user's perspective on GeoMx^TM digital spatial profiling.

01-07-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

01-07-2019

European journal of cancer (Oxford, England : 1990)

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

01-07-2019

Journal of oncology

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors.

12-06-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.

01-06-2019

Nature medicine

Combining checkpoint inhibition and targeted therapy in melanoma.

01-06-2019

Nature medicine

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-06-2019

Journal of immunotherapy (Hagerstown, Md. : 1997)

Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program.

31-05-2019

Cancer immunology, immunotherapy : CII

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

01-05-2019

The British journal of surgery

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.

01-04-2019

Oncotarget

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.

05-03-2019

European urology

The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

01-03-2019

Oncoimmunology

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

07-02-2019

Cell

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

07-02-2019

Oncoimmunology

Batf3⁺ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

05-02-2019

Cancer letters

Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.

01-02-2019

JAMA oncology

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

01-02-2019

European journal of cancer (Oxford, England : 1990)

An open-label, multicentre safety study of vemurafenib in patients with BRAF^V600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

01-01-2019

Nature medicine

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

01-11-2018

JAAD case reports

Remission of psoriasis during treatment with sorafenib.

01-11-2018

Cancer immunology, immunotherapy : CII

Targeting tumor-associated acidity in cancer immunotherapy.

01-09-2018

European journal of cancer (Oxford, England : 1990)

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.

01-09-2018